DelveInsight’s ‘Atopic Dermatitis (AD) – Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Atopic Dermatitis (AD) epidemiology in the 7MM.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2017-2030
The DelveInsight Atopic Dermatitis (AD) epidemiology report gives a thorough understanding of the Atopic Dermatitis (AD) by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Atopic Dermatitis (AD) in the US, Europe, and Japan. The report covers the detailed information of the Atopic Dermatitis (AD) epidemiology scenario in seven major countries (US, EU5, and Japan).
As per the National Eczema Association 2019, Atopic dermatitis exists with two other allergic conditions: asthma and hay fever (allergic rhinitis). People who have asthma and/or hay fever or who have family members who do are more likely to develop AD.
Atopic Dermatitis Epidemiology
The Atopic Dermatitis (AD) epidemiology division provide insights about historical and current Atopic Dermatitis (AD) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
DelveInsight analysts revealed that total Atopic dermatitis prevalent population in 7MM was estimated to be around 41,261,411 in 2017. Moreover, a higher Atopic dermatitis prevalence is observed in the United States approximately 19,460,609 cases, when compared with other geographies in 7MM, i.e., EU5 countries and Japan.
Among the AD patients, Females show higher proportion of Prevalence of AD as compared to males in the 7MM and China.
Atopic Dermatitis Epidemiology Segmentation
The Atopic Dermatitis (AD) epidemiology covered in the report provides historical as well as forecasted Atopic Dermatitis (AD) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.
Prevalence of Atopic Dermatitis in 7MM [2017–2030]
Gender-Specific Prevalent Cases of Atopic Dermatitis in 7MM [2017–2030]
Diagnosed and Treatable Cases of Atopic Dermatitis in the 7MM [2017–2030]
Age-specific Prevalent Cases of Atopic Dermatitis in 7MM [2017–2030]
Severity-Specific Prevalent Cases of Atopic Dermatitis in 7MM [2017–2030]
- 11-Year Forecast of Atopic Dermatitis (AD) epidemiology
- 7MM Coverage
- Total Cases of Atopic Dermatitis (AD)
- Total Cases of Atopic Dermatitis (AD) according to segmentation
- Diagnosed cases of Atopic Dermatitis (AD)
Table of contents
1. Key Insights
2. Executive Summary of Atopic Dermatitis (AD)
3. Atopic Dermatitis (AD): Disease Background and Overview
4. Patient Journey
5. Epidemiology and Patient Population
6. Treatment Algorithm, Current Treatment, and Medical Practices
7. KOL Views
8. Unmet Needs
10. DelveInsight Capabilities
*The table of contents is not exhaustive; will be provided in the final report
DelveInsight is a premier Business Consulting and Market Research firm, focused exclusively on the life science segment. With a wide array of smart end-to-end solutions, the firm helps the global Pharmaceutical and Bio-Tech companies formulate prudent business decisions for better growth in the market.
Browse through our vast repository from here.
Company Name: DelveInsight Business Research LLP
Contact Person: Vinita Rakheja
Email: Send Email
Address:304 S. Jones Blvd #2432
State: New York
Country: United States